Drug class
Tissue factor pathway inhibitor (TFPI) monoclonal antibody; procoagulant biologic
Mechanism of action
Binds the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), reducing TFPI-mediated inhibition of factor Xa and the tissue factor-factor VIIa complex and increasing thrombin generation.
General use cases
- Routine prophylaxis to prevent or reduce bleeding episodes in eligible adults and adolescent males aged 12 years and older with haemophilia A or B without factor VIII or IX inhibitors under the US HYMPTAVZI indication; not for treatment of acute bleeding
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
